NCT02337829 - Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

June 26, 2020

Study Completion Date

April 1, 2026

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Acalabrutinib (Arm A)

"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"

DRUG

Acalabrutinib (Arm B)

"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."

Trial Locations (1)

20892

Research Site, Bethesda